Potential effects of current drug therapies on cognitive impairment in patients with type 2 diabetes

Frontiers in Neuroendocrinology

Volumn 42, Issue , 2016, Pages 76-92

  Palleria, Caterina ^a   Leporini, Christian ^a   Maida, Francesca ^a   Succurro, Elena ^a   De Sarro, Giovambattista ^a   Arturi, Franco ^a   Russo, Emilio ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

Author keywords

Gliptins; GLP 1; Metformin; Neuroprotection; Sulfonylureas; Thiazolidinediones

Indexed keywords

ALOGLIPTIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EXENDIN 4; GHRELIN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SIRTUIN 1; SITAGLIPTIN; TOLBUTAMIDE; VILDAGLIPTIN; ANTIDIABETIC AGENT;

ALZHEIMER DISEASE; COGNITIVE DEFECT; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; MILD COGNITIVE IMPAIRMENT; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; COGNITIVE DYSFUNCTION; COMPLICATION; DIABETES MELLITUS, TYPE 2;

COGNITIVE DYSFUNCTION; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS;

EID: 84981743851     PISSN: 00913022     EISSN: 10956808     Source Type: Journal    
DOI: 10.1016/j.yfrne.2016.07.002     Document Type: Review

References (244)

1. Aarse, J., Herlitze, S., Manahan-Vaughan, D., The requirement of BDNF for hippocampal synaptic plasticity is experience-dependent. Hippocampus 26 (2015), 739–751.
2. Abbas, T., Faivre, E., Holscher, C., Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: interaction between type 2 diabetes and Alzheimer's disease. Behav. Brain Res. 205 (2009), 265–271.
3. Abbatecola, A.M., Lattanzio, F., Molinari, A.M., Cioffi, M., Mansi, L., Rambaldi, P., DiCioccio, L., Cacciapuoti, F., Canonico, R., Paolisso, G., Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care 33 (2010), 1706–1711.
4. Abdelmoneim, A.S., Hasenbank, S.E., Seubert, J.M., Brocks, D.R., Light, P.E., Simpson, S.H., Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes Obes. Metab. 14 (2012), 130–138.
5. Allard, J.S., Perez, E.J., Fukui, K., Carpenter, P., Ingram, D.K., Cabo, R., Prolonged metformin treatment leads to reduced transcription of Nrf2 and neurotrophic factors without cognitive impairment in older C57BL/6J mice. Behav. Brain Res. 301 (2015), 1–9.
6. Allard, J.S., Perez, E.J., Fukui, K., Carpenter, P., Ingram, D.K., Cabo, R., Prolonged metformin treatment leads to reduced transcription of Nrf2 and neurotrophic factors without cognitive impairment in older C57BL/6J mice. Behav. Brain Res. 301 (2016), 1–9.
7. Alzoubi, K.H., Khabour, O.F., Al-Azzam, S.I., Tashtoush, M.H., Mhaidat, N.M., Metformin eased cognitive impairment induced by chronic L-methionine administration: potential role of oxidative stress. Curr. Neuropharmacol. 12 (2014), 186–192.
8. American Diabetes, A., Standards of medical care in diabetes–2013. Diabetes Care 36:Suppl. 1 (2013), S11–S66.
9. Artero, S., Ancelin, M.L., Portet, F., Dupuy, A., Berr, C., Dartigues, J.F., Tzourio, C., Rouaud, O., Poncet, M., Pasquier, F., Auriacombe, S., Touchon, J., Ritchie, K., Risk profiles for mild cognitive impairment and progression to dementia are gender specific. J. Neurol. Neurosurg. Psychiatry 79 (2008), 979–984.
10. Arunachalam, G., Samuel, S.M., Marei, I., Ding, H., Triggle, C.R., Metformin modulates hyperglycaemia-induced endothelial senescence and apoptosis through SIRT1. Br. J. Pharmacol. 171 (2014), 523–535.
11. Arvanitakis, Z., Wilson, R.S., Bienias, J.L., Evans, D.A., Bennett, D.A., Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 61 (2004), 661–666.
12. Atcha, Z., Chen, W.S., Ong, A.B., Wong, F.K., Neo, A., Browne, E.R., Witherington, J., Pemberton, D.J., Cognitive enhancing effects of ghrelin receptor agonists. Psychopharmacology 206 (2009), 415–427.
13. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., Limousin, P., Foltynie, T., Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Investig. 123 (2013), 2730–2736.
14. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Kahan, J., Ell, P., Whitton, P., Wyse, R., Isaacs, T., Lees, A., Limousin, P., Foltynie, T., Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J. Parkinson's Disease 4 (2014), 337–344.
15. Babri, S., Badie, H.G., Khamenei, S., Seyedlar, M.O., Intrahippocampal insulin improves memory in a passive-avoidance task in male wistar rats. Brain Cogn. 64 (2007), 86–91.
16. Barazzoni, R., Zanetti, M., Stulle, M., Mucci, M.P., Pirulli, A., Dore, F., Panzetta, G., Vasile, A., Biolo, G., Guarnieri, G., Higher total ghrelin levels are associated with higher insulin-mediated glucose disposal in non-diabetic maintenance hemodialysis patients. Clin. Nutr. 27 (2008), 142–149.
17. Barber, A.J., Nakamura, M., Wolpert, E.B., Reiter, C.E., Seigel, G.M., Antonetti, D.A., Gardner, T.W., Insulin rescues retinal neurons from apoptosis by a phosphatidylinositol 3-kinase/Akt-mediated mechanism that reduces the activation of caspase-3. J. Biol. Chem. 276 (2001), 32814–32821.
18. Bauman, W.A., Shaw, S., Jayatilleke, E., Spungen, A.M., Herbert, V., Increased intake of calcium reverses vitamin B12 malabsorption induced by metformin. Diabetes Care 23 (2000), 1227–1231.
19. Baura, G.D., Foster, D.M., Porte, D. Jr., Kahn, S.E., Bergman, R.N., Cobelli, C., Schwartz, M.W., Saturable transport of insulin from plasma into the central nervous system of dogs in vivo. A mechanism for regulated insulin delivery to the brain. J. Clin. Investig. 92 (1993), 1824–1830.
20. Benedict, C., Hallschmid, M., Hatke, A., Schultes, B., Fehm, H.L., Born, J., Kern, W., Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29 (2004), 1326–1334.
21. Benedict, C., Kern, W., Schultes, B., Born, J., Hallschmid, M., Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J. Clin. Endocrinol. Metab. 93 (2008), 1339–1344.
22. Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Ronnholm, H., Wikstrom, L., Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J. Neurosci. Res. 86 (2008), 326–338.
23. Biessels, G.J., Kamal, A., Ramakers, G.M., Urban, I.J., Spruijt, B.M., Erkelens, D.W., Gispen, W.H., Place learning and hippocampal synaptic plasticity in streptozotocin-induced diabetic rats. Diabetes 45 (1996), 1259–1266.
24. Biessels, G.J., Reagan, L.P., Hippocampal insulin resistance and cognitive dysfunction. Nat. Rev. Neurosci. 16 (2015), 660–671.
25. Biessels, G.J., Staekenborg, S., Brunner, E., Brayne, C., Scheltens, P., Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 5 (2006), 64–74.
26. Braidy, N., Jayasena, T., Poljak, A., Sachdev, P.S., Sirtuins in cognitive ageing and Alzheimer's disease. Curr. Opin. Psychiatry 25 (2012), 226–230.
27. Brauer, R., Bhaskaran, K., Chaturvedi, N., Dexter, D.T., Smeeth, L., Douglas, I., Glitazone treatment and incidence of Parkinson's disease among people with diabetes: a retrospective cohort study. PLoS Med., 12, 2015, e1001854.
28. Brewster, A.L., Lugo, J.N., Patil, V.V., Lee, W.L., Qian, Y., Vanegas, F., Anderson, A.E., Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage. PLoS ONE, 8, 2013, e57808.
29. Brownlee, M., Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001), 813–820.
30. Brownlee, M., The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 (2005), 1615–1625.
31. Bruce, D.G., Davis, W.A., Casey, G.P., Clarnette, R.M., Brown, S.G., Jacobs, I.G., Almeida, O.P., Davis, T.M., Severe hypoglycaemia and cognitive impairment in older patients with diabetes: the fremantle diabetes study. Diabetologia 52 (2009), 1808–1815.
32. Brundel, M., Kappelle, L.J., Biessels, G.J., Brain imaging in type 2 diabetes. Eur. Neuropsychopharmacol.: J. Eur. College Neuropsychopharmacol. 24 (2014), 1967–1981.
33. Buse, J.B., Rosenstock, J., Sesti, G., Schmidt, W.E., Montanya, E., Brett, J.H., Zychma, M., Blonde, L., Group, L.-S., Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374 (2009), 39–47.
34. Cahill, S.P., Hatchard, T., Abizaid, A., Holahan, M.R., An examination of early neural and cognitive alterations in hippocampal-spatial function of ghrelin receptor-deficient rats. Behav. Brain Res. 264 (2014), 105–115.
35. Cai, H.Y., Holscher, C., Yue, X.H., Zhang, S.X., Wang, X.H., Qiao, F., Yang, W., Qi, J.S., Lixisenatide rescues spatial memory and synaptic plasticity from amyloid beta protein-induced impairments in rats. Neuroscience 277 (2014), 6–13.
36. Campbell, N.L., Unverzagt, F., LaMantia, M.A., Khan, B.A., Boustani, M.A., Risk factors for the progression of mild cognitive impairment to dementia. Clin. Geriatr. Med. 29 (2013), 873–893.
37. Cao, Y., Jiang, X., Ma, H., Wang, Y., Xue, P., Liu, Y., SIRT1 and insulin resistance. J. Diabetes Compl. 30 (2016), 178–183.
38. Cardoso, S., Correia, S.C., Santos, R.X., Carvalho, C., Candeias, E., Duarte, A.I., Placido, A.I., Santos, M.S., Moreira, P.I., Hyperglycemia, hypoglycemia and dementia: role of mitochondria and uncoupling proteins. Curr. Mol. Med. 13 (2013), 586–601.
39. Cardoso, S., Santos, M.S., Moreno, A., Moreira, P.I., UCP2 and ANT differently modulate proton-leak in brain mitochondria of long-term hyperglycemic and recurrent hypoglycemic rats. J. Bioenerg. Biomembr. 45 (2013), 397–407.
40. Carlezon, W.A. Jr., Duman, R.S., Nestler, E.J., The many faces of CREB. Trends Neurosci. 28 (2005), 436–445.
41. Carlini, V.P., Monzon, M.E., Varas, M.M., Cragnolini, A.B., Schioth, H.B., Scimonelli, T.N., de Barioglio, S.R., Ghrelin increases anxiety-like behavior and memory retention in rats. Biochem. Biophys. Res. Commun. 299 (2002), 739–743.
42. Caton, P.W., Nayuni, N.K., Kieswich, J., Khan, N.Q., Yaqoob, M.M., Corder, R., Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J. Endocrinol. 205 (2010), 97–106.
43. Cavalier, M., Crouzin, N., Ben Sedrine, A., de Jesus Ferreira, M.C., Guiramand, J., Cohen-Solal, C., Fehrentz, J.A., Martinez, J., Barbanel, G., Vignes, M., Involvement of PKA and ERK pathways in ghrelin-induced long-lasting potentiation of excitatory synaptic transmission in the CA1 area of rat hippocampus. Eur. J. Neurosci. 42 (2015), 2568–2576.
44. Chatterjee, S., Peters, S.A., Woodward, M., Mejia Arango, S., Batty, G.D., Beckett, N., Beiser, A., Borenstein, A.R., Crane, P.K., Haan, M., Hassing, L.B., Hayden, K.M., Kiyohara, Y., Larson, E.B., Li, C.Y., Ninomiya, T., Ohara, T., Peters, R., Russ, T.C., Seshadri, S., Strand, B.H., Walker, R., Xu, W., Huxley, R.R., Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care 39 (2016), 300–307.
45. Chen, F., Dong, R.R., Zhong, K.L., Ghosh, A., Tang, S.S., Long, Y., Hu, M., Miao, M.X., Liao, J.M., Sun, H.B., Kong, L.Y., Hong, H., Antidiabetic drugs restore abnormal transport of amyloid-beta across the blood-brain barrier and memory impairment in db/db mice. Neuropharmacology 101 (2016), 123–136.
46. Chen, L., Xing, T., Wang, M., Miao, Y., Tang, M., Chen, J., Li, G., Ruan, D.Y., Local infusion of ghrelin enhanced hippocampal synaptic plasticity and spatial memory through activation of phosphoinositide 3-kinase in the dentate gyrus of adult rats. Eur. J. Neurosci. 33 (2011), 266–275.
47. Chen, Y.C., Wu, J.S., Tsai, H.D., Huang, C.Y., Chen, J.J., Sun, G.Y., Lin, T.N., Peroxisome proliferator-activated receptor gamma (PPAR-gamma) and neurodegenerative disorders. Mol. Neurobiol. 46 (2012), 114–124.
48. Cheng, C.M., Mervis, R.F., Niu, S.L., Salem, N. Jr., Witters, L.A., Tseng, V., Reinhardt, R., Bondy, C.A., Insulin-like growth factor 1 is essential for normal dendritic growth. J. Neurosci. Res. 73 (2003), 1–9.
49. Cheng, D., Noble, J., Tang, M.X., Schupf, N., Mayeux, R., Luchsinger, J.A., Type 2 diabetes and late-onset Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 31 (2011), 424–430.
50. Cheng, G., Huang, C., Deng, H., Wang, H., Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Internal Med. J. 42 (2012), 484–491.
51. Chong, Z.Z., Shang, Y.C., Zhang, L., Wang, S., Maiese, K., Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders. Oxid. Med. Cell. Long. 3 (2010), 374–391.
52. Christensen, M., Knop, F.K., Vilsboll, T., Holst, J.J., Lixisenatide for type 2 diabetes mellitus. Expert Opin. Investig. Drugs 20 (2011), 549–557.
53. Claxton, A., Baker, L.D., Hanson, A., Trittschuh, E.H., Cholerton, B., Morgan, A., Callaghan, M., Arbuckle, M., Behl, C., Craft, S., Long acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia. J. Alzheimer's Disease: JAD 45 (2015), 1269–1270.
54. Combs, C.K., Johnson, D.E., Karlo, J.C., Cannady, S.B., Landreth, G.E., Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J. Neurosci. 20 (2000), 558–567.
55. Costa, A., Peppe, A., Carlesimo, G.A., Zabberoni, S., Scalici, F., Caltagirone, C., Angelucci, F., Brain-derived neurotrophic factor serum levels correlate with cognitive performance in Parkinson's disease patients with mild cognitive impairment. Front. Behav. Neurosci., 9, 2015, 253.
56. Costales, J., Kolevzon, A., The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders. Neurosci. Biobehav. Rev. 63 (2016), 207–222.
57. Costello, D.A., Claret, M., Al-Qassab, H., Plattner, F., Irvine, E.E., Choudhury, A.I., Giese, K.P., Withers, D.J., Pedarzani, P., Brain deletion of insulin receptor substrate 2 disrupts hippocampal synaptic plasticity and metaplasticity. PLoS ONE, 7, 2012, e31124.
58. Craft, S., Baker, L.D., Montine, T.J., Minoshima, S., Watson, G.S., Claxton, A., Arbuckle, M., Callaghan, M., Tsai, E., Plymate, S.R., Green, P.S., Leverenz, J., Cross, D., Gerton, B., Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 69 (2012), 29–38.
59. Crane, P.K., Walker, R., Larson, E.B., Glucose levels and risk of dementia. N. Engl. J. Med. 369 (2013), 1863–1864.
60. D'Amico, M., Di Filippo, C., Marfella, R., Abbatecola, A.M., Ferraraccio, F., Rossi, F., Paolisso, G., Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice. Exp. Gerontol. 45 (2010), 202–207.
61. D'Ercole, A.J., Ye, P., O'Kusky, J.R., Mutant mouse models of insulin-like growth factor actions in the central nervous system. Neuropeptides 36 (2002), 209–220.
62. Dash, S.K., Cognitive impairment and diabetes. Recent Pat. Endocr., Metab. Immune Drug Discov. 7 (2013), 155–165.
63. De Felice, F.G., Vieira, M.N., Bomfim, T.R., Decker, H., Velasco, P.T., Lambert, M.P., Viola, K.L., Zhao, W.Q., Ferreira, S.T., Klein, W.L., Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of Abeta oligomers. Proc. Natl. Acad. Sci. USA 106 (2009), 1971–1976.
64. de la Monte, S.M., Longato, L., Tong, M., Wands, J.R., Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr. Opin. Investig. Drugs 10 (2009), 1049–1060.
65. Diano, S., Farr, S.A., Benoit, S.C., McNay, E.C., da Silva, I., Horvath, B., Gaskin, F.S., Nonaka, N., Jaeger, L.B., Banks, W.A., Morley, J.E., Pinto, S., Sherwin, R.S., Xu, L., Yamada, K.A., Sleeman, M.W., Tschop, M.H., Horvath, T.L., Ghrelin controls hippocampal spine synapse density and memory performance. Nat. Neurosci. 9 (2006), 381–388.
66. Dietrich, M.O., Horvath, T.L., The role of mitochondrial uncoupling proteins in lifespan. Pflugers Arch. 459 (2010), 269–275.
67. Du, L.L., Xie, J.Z., Cheng, X.S., Li, X.H., Kong, F.L., Jiang, X., Ma, Z.W., Wang, J.Z., Chen, C., Zhou, X.W., Activation of sirtuin 1 attenuates cerebral ventricular streptozotocin-induced tau hyperphosphorylation and cognitive injuries in rat hippocampi. Age 36 (2014), 613–623.
68. Duarte, A.I., Proenca, T., Oliveira, C.R., Santos, M.S., Rego, A.C., Insulin restores metabolic function in cultured cortical neurons subjected to oxidative stress. Diabetes 55 (2006), 2863–2870.
69. Duarte, A.I., Santos, P., Oliveira, C.R., Santos, M.S., Rego, A.C., Insulin neuroprotection against oxidative stress is mediated by Akt and GSK-3beta signaling pathways and changes in protein expression. Biochim. Biophys. Acta 1783 (2008), 994–1002.
70. During, M.J., Cao, L., Zuzga, D.S., Francis, J.S., Fitzsimons, H.L., Jiao, X., Bland, R.J., Klugmann, M., Banks, W.A., Drucker, D.J., Haile, C.N., Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med. 9 (2003), 1173–1179.
71. Egefjord, L., Gejl, M., Moller, A., Braendgaard, H., Gottrup, H., Antropova, O., Moller, N., Poulsen, H.E., Gjedde, A., Brock, B., Rungby, J., Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer s disease – protocol for a controlled, randomized double-blinded trial. Danish Med. J., 59, 2012, A4519.
72. El Batsh, M.M., El Batch, M.M., Shafik, N.M., Younos, I.H., Favorable effects of vildagliptin on metabolic and cognitive dysfunctions in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 769 (2015), 297–305.
73. El-Mir, M.Y., Detaille, D., Gloria, R.V., Delgado-Esteban, M., Guigas, B., Attia, S., Fontaine, E., Almeida, A., Leverve, X., Neuroprotective role of antidiabetic drug metformin against apoptotic cell death in primary cortical neurons. J. Mol. Neurosci.: MN 34 (2008), 77–87.
74. Elias, M.F., Elias, P.K., Sullivan, L.M., Wolf, P.A., D'Agostino, R.B., Obesity, diabetes and cognitive deficit: the Framingham Heart Study. Neurobiol. Aging 26:Suppl. 1 (2005), 11–16.
75. Esser, N., Legrand-Poels, S., Piette, J., Scheen, A.J., Paquot, N., Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res. Clin. Pract. 105 (2014), 141–150.
76. Fava, S., Glycaemic control: a balancing act or a different approach?. Curr. Diabetes Rev. 10 (2014), 124–130.
77. Feinkohl, I., Aung, P.P., Keller, M., Robertson, C.M., Morling, J.R., McLachlan, S., Deary, I.J., Frier, B.M., Strachan, M.W., Price, J.F., Edinburgh Type 2 Diabetes Study, I., Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 37 (2014), 507–515.
78. Ferrini, F., Salio, C., Lossi, L., Merighi, A., Ghrelin in central neurons. Curr. Neuropharmacol. 7 (2009), 37–49.
79. Freude, S., Plum, L., Schnitker, J., Leeser, U., Udelhoven, M., Krone, W., Bruning, J.C., Schubert, M., Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 54 (2005), 3343–3348.
80. Gao, J., Wang, W.Y., Mao, Y.W., Graff, J., Guan, J.S., Pan, L., Mak, G., Kim, D., Su, S.C., Tsai, L.H., A novel pathway regulates memory and plasticity via SIRT1 and miR-134. Nature 466 (2010), 1105–1109.
81. Gault, V.A., Lennox, R., Flatt, P.R., Sitagliptin, a dipeptidyl peptidase-4 inhibitor, improves recognition memory, oxidative stress and hippocampal neurogenesis and upregulates key genes involved in cognitive decline. Diabetes Obes. Metab. 17 (2015), 403–413.
82. Geijselaers, S.L., Sep, S.J., Stehouwer, C.D., Biessels, G.J., Glucose regulation, cognition, and brain MRI in type 2 diabetes: a systematic review. Lancet Diabetes Endocrinol. 3 (2015), 75–89.
83. Gejl, M., Gjedde, A., Egefjord, L., Moller, A., Hansen, S.B., Vang, K., Rodell, A., Braendgaard, H., Gottrup, H., Schacht, A., Moller, N., Brock, B., Rungby, J., In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind clinical trial. Front. Aging Neurosci., 8, 2016, 108.
84. Gengler, S., McClean, P.L., McCurtin, R., Gault, V.A., Holscher, C., Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiol. Aging 33 (2012), 265–276.
85. Gilman, C.P., Perry, T., Furukawa, K., Grieg, N.H., Egan, J.M., Mattson, M.P., Glucagon-like peptide 1 modulates calcium responses to glutamate and membrane depolarization in hippocampal neurons. J. Neurochem. 87 (2003), 1137–1144.
86. Glasper, E.R., Llorens-Martin, M.V., Leuner, B., Gould, E., Trejo, J.L., Blockade of insulin-like growth factor-I has complex effects on structural plasticity in the hippocampus. Hippocampus 20 (2010), 706–712.
87. Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A.M., Irizarry, M., Craft, S., Landreth, G., Linnamagi, U., Sawchak, S., Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study. Dement. Geriatr. Cogn. Disord. 30 (2010), 131–146.
88. Grillo, C.A., Piroli, G.G., Lawrence, R.C., Wrighten, S.A., Green, A.J., Wilson, S.P., Sakai, R.R., Kelly, S.J., Wilson, M.A., Mott, D.D., Reagan, L.P., Hippocampal insulin resistance impairs spatial learning and synaptic plasticity. Diabetes 64 (2015), 3927–3936.
89. Gupta, A., Bisht, B., Dey, C.S., Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes. Neuropharmacology 60 (2011), 910–920.
90. Haas, C.B., Kalinine, E., Zimmer, E.R., Hansel, G., Brochier, A.W., Oses, J.P., Portela, L.V., Muller, A.P., Brain Insulin Administration Triggers Distinct Cognitive and Neurotrophic Responses in Young and Aged Rats. Mol. Neurobiol., 2015 (in press).
91. Hamilton, A., Holscher, C., Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. NeuroReport 20 (2009), 1161–1166.
92. Hamilton, A., Patterson, S., Porter, D., Gault, V.A., Holscher, C., Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. J. Neurosci. Res. 89 (2011), 481–489.
93. Hansen, H.H., Barkholt, P., Fabricius, K., Jelsing, J., Terwel, D., Pyke, C., Knudsen, L.B., Vrang, N., The GLP-1 receptor agonist liraglutide reduces pathology-specific tau phosphorylation and improves motor function in a transgenic hTauP301L mouse model of tauopathy. Brain Res. 1634 (2016), 158–170.
94. Hansen, H.H., Fabricius, K., Barkholt, P., Niehoff, M.L., Morley, J.E., Jelsing, J., Pyke, C., Knudsen, L.B., Farr, S.A., Vrang, N., The GLP-1 receptor agonist liraglutide improves memory function and increases hippocampal CA1 neuronal numbers in a senescence-accelerated mouse model of Alzheimer's disease. J. Alzheimer's Disease: JAD 46 (2015), 877–888.
95. Harkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A.E., Biggs, C.S., Whitton, P.S., Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J. Neuroinflam., 5, 2008, 19.
96. Heikkila, O., Lundbom, N., Timonen, M., Groop, P.H., Heikkinen, S., Makimattila, S., Evidence for abnormal glucose uptake or metabolism in thalamus during acute hyperglycaemia in type 1 diabetes – a 1H MRS study. Metab. Brain Dis. 25 (2010), 227–234.
97. Heni, M., Hennige, A.M., Peter, A., Siegel-Axel, D., Ordelheide, A.M., Krebs, N., Machicao, F., Fritsche, A., Haring, H.U., Staiger, H., Insulin promotes glycogen storage and cell proliferation in primary human astrocytes. PLoS ONE, 6, 2011, e21594.
98. Herold, S., Jagasia, R., Merz, K., Wassmer, K., Lie, D.C., CREB signalling regulates early survival, neuronal gene expression and morphological development in adult subventricular zone neurogenesis. Mol. Cell. Neurosci. 46 (2011), 79–88.
99. Heyward, F.D., Walton, R.G., Carle, M.S., Coleman, M.A., Garvey, W.T., Sweatt, J.D., Adult mice maintained on a high-fat diet exhibit object location memory deficits and reduced hippocampal SIRT1 gene expression. Neurobiol. Learn. Mem. 98 (2012), 25–32.
100. Holscher, C., The role of GLP-1 in neuronal activity and neurodegeneration. Vitam. Horm. 84 (2010), 331–354.
101. Holst, J.J., The physiology of glucagon-like peptide 1. Physiol. Rev. 87 (2007), 1409–1439.
102. Hsu, C.C., Wahlqvist, M.L., Lee, M.S., Tsai, H.N., Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin. J. Alzheimer's Disease: JAD 24 (2011), 485–493.
103. Hu, A., Yuan, H., Wu, L., Chen, R., Chen, Q., Zhang, T., Wang, Z., Liu, P., Zhu, X., The effect of constitutive over-expression of insulin-like growth factor 1 on the cognitive function in aged mice. Brain Res. 1631 (2016), 204–213.
104. Huang, Y.C., Hsu, C.C., Lin, W.C., Yin, T.K., Huang, C.W., Wang, P.W., Chang, H.H., Chiu, N.T., Effects of metformin on the cerebral metabolic changes in type 2 diabetic patients. Sci. World J., 2014, 2014, 694326.
105. Huffman, D.M., Farias Quipildor, G., Mao, K., Zhang, X., Wan, J., Apontes, P., Cohen, P., Barzilai, N., Central insulin-like growth factor-1 (IGF-1) restores whole-body insulin action in a model of age-related insulin resistance and IGF-1 decline. Aging Cell 15 (2016), 181–186.
106. Hwang, I.K., Kim, I.Y., Joo, E.J., Shin, J.H., Choi, J.W., Won, M.H., Yoon, Y.S., Seong, J.K., Metformin normalizes type 2 diabetes-induced decrease in cell proliferation and neuroblast differentiation in the rat dentate gyrus. Neurochem. Res. 35 (2010), 645–650.
107. Imfeld, P., Bodmer, M., Jick, S.S., Meier, C.R., Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: a population-based case-control study. J. Am. Geriatr. Soc. 60 (2012), 916–921.
108. Inestrosa, N.C., Carvajal, F.J., Zolezzi, J.M., Tapia-Rojas, C., Serrano, F., Karmelic, D., Toledo, E.M., Toro, A., Toro, J., Santos, M.J., Peroxisome proliferators reduce spatial memory impairment, synaptic failure, and neurodegeneration in brains of a double transgenic mice model of Alzheimer's disease. J. Alzheimer's Disease: JAD 33 (2013), 941–959.
109. Inestrosa, N.C., Godoy, J.A., Quintanilla, R.A., Koenig, C.S., Bronfman, M., Peroxisome proliferator-activated receptor gamma is expressed in hippocampal neurons and its activation prevents beta-amyloid neurodegeneration: role of Wnt signaling. Exp. Cell Res. 304 (2005), 91–104.
110. Inoue, T., Inoguchi, T., Sonoda, N., Hendarto, H., Makimura, H., Sasaki, S., Yokomizo, H., Fujimura, Y., Miura, D., Takayanagi, R., GLP-1 analog liraglutide protects against cardiac steatosis, oxidative stress and apoptosis in streptozotocin-induced diabetic rats. Atherosclerosis 240 (2015), 250–259.
111. Investigators, N.E.T.i.P.D.F.-Z., Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 14 (2015), 795–803.
112. Irvine, E.E., Drinkwater, L., Radwanska, K., Al-Qassab, H., Smith, M.A., O'Brien, M., Kielar, C., Choudhury, A.I., Krauss, S., Cooper, J.D., Withers, D.J., Giese, K.P., Insulin receptor substrate 2 is a negative regulator of memory formation. Learn. Mem. 18 (2011), 375–383.
113. Isacson, R., Nielsen, E., Dannaeus, K., Bertilsson, G., Patrone, C., Zachrisson, O., Wikstrom, L., The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test. Eur. J. Pharmacol. 650 (2011), 249–255.
114. Iwai, T., Sawabe, T., Tanimitsu, K., Suzuki, M., Sasaki-Hamada, S., Oka, J., Glucagon-like peptide-1 protects synaptic and learning functions from neuroinflammation in rodents. J. Neurosci. Res. 92 (2014), 446–454.
115. Ji, C., Xue, G.F., Lijun, C., Feng, P., Li, D., Li, L., Li, G., Holscher, C., A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF. Brain Res. 1634 (2016), 1–11.
116. Jiang, L.Y., Tang, S.S., Wang, X.Y., Liu, L.P., Long, Y., Hu, M., Liao, M.X., Ding, Q.L., Hu, W., Li, J.C., Hong, H., PPARgamma agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus. CNS Neurosci. Ther. 18 (2012), 659–666.
117. Kakefuda, K., Fujita, Y., Oyagi, A., Hyakkoku, K., Kojima, T., Umemura, K., Tsuruma, K., Shimazawa, M., Ito, M., Nozawa, Y., Hara, H., Sirtuin 1 overexpression mice show a reference memory deficit, but not neuroprotection. Biochem. Biophys. Res. Commun. 387 (2009), 784–788.
118. Kariharan, T., Nanayakkara, G., Parameshwaran, K., Bagasrawala, I., Ahuja, M., Abdel-Rahman, E., Amin, A.T., Dhanasekaran, M., Suppiramaniam, V., Amin, R.H., Central activation of PPAR-gamma ameliorates diabetes induced cognitive dysfunction and improves BDNF expression. Neurobiol. Aging 36 (2015), 1451–1461.
119. Kautzky-Willer, A., Harreiter, J., Pacini, G., Sex and gender differences in risk, pathophysiology and complications of Type 2 diabetes mellitus. Endocr. Rev. 37 (2016), 278–316.
120. Khanfar, M.A., AbuKhader, M.M., Alqtaishat, S., Taha, M.O., Pharmacophore modeling, homology modeling, and in silico screening reveal mammalian target of rapamycin inhibitory activities for sotalol, glyburide, metipranolol, sulfamethizole, glipizide, and pioglitazone. J. Mol. Graph. Model. 42 (2013), 39–49.
121. Kharroubi, A.T., Darwish, H.M., Diabetes mellitus: the epidemic of the century. World J. Diabetes 6 (2015), 850–867.
122. Kida, S., Serita, T., Functional roles of CREB as a positive regulator in the formation and enhancement of memory. Brain Res. Bull. 105 (2014), 17–24.
123. Kleinridders, A., Ferris, H.A., Cai, W., Kahn, C.R., Insulin action in brain regulates systemic metabolism and brain function. Diabetes 63 (2014), 2232–2243.
124. Koekkoek, P.S., Rutten, G.E., Biessels, G.J., Cognitive disorders in diabetic patients. Handb. Clin. Neurol. 126 (2014), 145–166.
125. Korbonits, M., Goldstone, A.P., Gueorguiev, M., Grossman, A.B., Ghrelin – a hormone with multiple functions. Front. Neuroendocrinol. 25 (2004), 27–68.
126. Kornelius, E., Lin, C.L., Chang, H.H., Li, H.H., Huang, W.N., Yang, Y.S., Lu, Y.L., Peng, C.H., Huang, C.N., DPP-4 inhibitor linagliptin attenuates abeta-induced cytotoxicity through activation of AMPK in neuronal cells. CNS Neurosci. Ther. 21 (2015), 549–557.
127. Korol, S.V., Jin, Z., Babateen, O., Birnir, B., GLP-1 and exendin-4 transiently enhance GABAA receptor-mediated synaptic and tonic currents in rat hippocampal CA3 pyramidal neurons. Diabetes 64 (2015), 79–89.
128. Kosaraju, J., Murthy, V., Khatwal, R.B., Dubala, A., Chinni, S., Muthureddy Nataraj, S.K., Basavan, D., Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. J. Pharm. Pharmacol. 65 (2013), 1773–1784.
129. Landreth, G., Therapeutic use of agonists of the nuclear receptor PPARgamma in Alzheimer's disease. Curr. Alzheimer Res. 4 (2007), 159–164.
130. Leal, G., Afonso, P.M., Salazar, I.L., Duarte, C.B., Regulation of hippocampal synaptic plasticity by BDNF. Brain Res. 1621 (2015), 82–101.
131. Lee, C.W., Shih, Y.H., Wu, S.Y., Yang, T., Lin, C., Kuo, Y.M., Hypoglycemia induces tau hyperphosphorylation. Curr. Alzheimer Res. 10 (2013), 298–308.
132. Lennox, R., Flatt, P.R., Gault, V.A., Lixisenatide improves recognition memory and exerts neuroprotective actions in high-fat fed mice. Peptides 61 (2014), 38–47.
133. Lennox, R., Porter, D.W., Flatt, P.R., Gault, V.A., (Val(8))GLP-1-Glu-PAL: a GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and beta-cell function in high-fat-fed mice. ChemMedChem 8 (2013), 595–602.
134. Leporini, C., De Sarro, G., Russo, E., Adherence to therapy and adverse drug reactions: is there a link?. Exp. Opin. Drug Safety 13:Suppl. 1 (2014), S41–S55.
135. Li, E., Chung, H., Kim, Y., Kim, D.H., Ryu, J.H., Sato, T., Kojima, M., Park, S., Ghrelin directly stimulates adult hippocampal neurogenesis: implications for learning and memory. Endocr. J. 60 (2013), 781–789.
136. Li, M., Li, S., Li, Y., Liraglutide promotes cortical neurite outgrowth via the MEK-ERK pathway. Cell. Mol. Neurobiol. 35 (2015), 987–993.
137. Li, W., Huang, E., An update on type 2 diabetes mellitus as a risk factor for dementia. J. Alzheimer's Disease: JAD 53 (2016), 393–402.
138. Lichtenwalner, R.J., Forbes, M.E., Bennett, S.A., Lynch, C.D., Sonntag, W.E., Riddle, D.R., Intracerebroventricular infusion of insulin-like growth factor-I ameliorates the age-related decline in hippocampal neurogenesis. Neuroscience 107 (2001), 603–613.
139. Liu, L.P., Yan, T.H., Jiang, L.Y., Hu, W., Hu, M., Wang, C., Zhang, Q., Long, Y., Wang, J.Q., Li, Y.Q., Hu, M., Hong, H., Pioglitazone ameliorates memory deficits in streptozotocin-induced diabetic mice by reducing brain beta-amyloid through PPARgamma activation. Acta Pharmacol. Sin. 34 (2013), 455–463.
140. Liu, Y., Yao, Z., Zhang, L., Zhu, H., Deng, W., Qin, C., Insulin induces neurite outgrowth via SIRT1 in SH-SY5Y cells. Neuroscience 238 (2013), 371–380.
141. Lizcano, J.M., Alessi, D.R., The insulin signalling pathway. Curr. Biol.: CB 12 (2002), R236–R238.
142. Logue, J., Walker, J.J., Colhoun, H.M., Leese, G.P., Lindsay, R.S., McKnight, J.A., Morris, A.D., Pearson, D.W., Petrie, J.R., Philip, S., Wild, S.H., Sattar, N., Scottish Diabetes Research Network Epidemiology, G., Do men develop type 2 diabetes at lower body mass indices than women?. Diabetologia 54 (2011), 3003–3006.
143. Lonze, B.E., Ginty, D.D., Function and regulation of CREB family transcription factors in the nervous system. Neuron 35 (2002), 605–623.
144. Lu, B., Nagappan, G., Lu, Y., BDNF and synaptic plasticity, cognitive function, and dysfunction. Handb. Exp. Pharmacol. 220 (2014), 223–250.
145. Lu, F.P., Chan, D.C., Kuo, H.K., Wu, S.C., Sex differences in the impact of diabetes on the risk of geriatric conditions. Geriatr. Gerontol. Int. 13 (2013), 116–122.
146. Luchsinger, J.A., Reitz, C., Patel, B., Tang, M.X., Manly, J.J., Mayeux, R., Relation of diabetes to mild cognitive impairment. Arch. Neurol. 64 (2007), 570–575.
147. Lupien, S.B., Bluhm, E.J., Ishii, D.N., Systemic insulin-like growth factor-I administration prevents cognitive impairment in diabetic rats, and brain IGF regulates learning/memory in normal adult rats. J. Neurosci. Res. 74 (2003), 512–523.
148. Ma, D.L., Chen, F.Q., Xu, W.J., Yue, W.Z., Yuan, G., Yang, Y., Early intervention with glucagon-like peptide 1 analog liraglutide prevents tau hyperphosphorylation in diabetic db/db mice. J. Neurochem. 135 (2015), 301–308.
149. Ma, L., Shao, Z., Wang, R., Zhao, Z., Dong, W., Zhang, J., Zhang, X., Sheng, S., Ji, Z., Zhang, J., Rosiglitazone improves learning and memory ability in rats with type 2 diabetes through the insulin signaling pathway. Am. J. Med. Sci. 350 (2015), 121–128.
150. Ma, L.Y., Zhang, D.M., Tang, Y., Lu, Y., Zhang, Y., Gao, Y., Xia, L., Zhao, K.X., Chai, L.Y., Xiao, Q., Ghrelin-attenuated cognitive dysfunction in streptozotocin-induced diabetic rats. Alzheimer Dis. Assoc. Disord. 25 (2011), 352–363.
151. Ma, T., Du, X., Pick, J.E., Sui, G., Brownlee, M., Klann, E., Glucagon-like peptide-1 cleavage product GLP-1(9–36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice. J. Neurosci. 32 (2012), 13701–13708.
152. Maimaiti, S., Anderson, K.L., DeMoll, C., Brewer, L.D., Rauh, B.A., Gant, J.C., Blalock, E.M., Porter, N.M., Thibault, O., Intranasal insulin improves age-related cognitive deficits and reverses electrophysiological correlates of brain aging. J. Gerontol. Ser. A, Biol. Sci. Med. Sci. 71 (2016), 30–39.
153. Martin, E.D., Sanchez-Perez, A., Trejo, J.L., Martin-Aldana, J.A., Cano Jaimez, M., Pons, S., Acosta Umanzor, C., Menes, L., White, M.F., Burks, D.J., IRS-2 deficiency impairs NMDA receptor-dependent long-term potentiation. Cereb. Cortex 22 (2012), 1717–1727.
154. Matsui, Y., Tanizaki, Y., Arima, H., Yonemoto, K., Doi, Y., Ninomiya, T., Sasaki, K., Iida, M., Iwaki, T., Kanba, S., Kiyohara, Y., Incidence and survival of dementia in a general population of Japanese elderly: the Hisayama study. J. Neurol. Neurosurg. Psychiatry 80 (2009), 366–370.
155. Mattson, M.P., Zhang, Y., Bose, S., Growth factors prevent mitochondrial dysfunction, loss of calcium homeostasis, and cell injury, but not ATP depletion in hippocampal neurons deprived of glucose. Exp. Neurol. 121 (1993), 1–13.
156. McClean, P.L., Holscher, C., Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. Neuropharmacology 76:Pt A (2014), 57–67.
157. McClean, P.L., Holscher, C., Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease. Neuropharmacology 86 (2014), 241–258.
158. McClean, P.L., Parthsarathy, V., Faivre, E., Holscher, C., The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. J. Neurosci. 31 (2011), 6587–6594.
159. McCormack, P.L., Exenatide twice daily: a review of its use in the management of patients with type 2 diabetes mellitus. Drugs 74 (2014), 325–351.
160. McCrimmon, R., The mechanisms that underlie glucose sensing during hypoglycaemia in diabetes. Diabetic Med.: J. British Diabetic Assoc. 25 (2008), 513–522.
161. McGill, J.B., Vlajnic, A., Knutsen, P.G., Recklein, C., Rimler, M., Fisher, S.J., Effect of gender on treatment outcomes in type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 102 (2013), 167–174.
162. McGovern, S.F., Hunter, K., Holscher, C., Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain. Brain Res. 1473 (2012), 204–213.
163. Merz, K., Herold, S., Lie, D.C., CREB in adult neurogenesis–master and partner in the development of adult-born neurons?. Eur. J. Neurosci. 33 (2011), 1078–1086.
164. Michan, S., Li, Y., Chou, M.M., Parrella, E., Ge, H., Long, J.M., Allard, J.S., Lewis, K., Miller, M., Xu, W., Mervis, R.F., Chen, J., Guerin, K.I., Smith, L.E., McBurney, M.W., Sinclair, D.A., Baudry, M., de Cabo, R., Longo, V.D., SIRT1 is essential for normal cognitive function and synaptic plasticity. J. Neurosci. 30 (2010), 9695–9707.
165. Moloney, A.M., Griffin, R.J., Timmons, S., O'Connor, R., Ravid, R., O'Neill, C., Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol. Aging 31 (2010), 224–243.
166. Moon, M., Cha, M.Y., Mook-Jung, I., Impaired hippocampal neurogenesis and its enhancement with ghrelin in 5XFAD mice. J. Alzheimer's Disease: JAD 41 (2014), 233–241.
167. Moon, M., Kim, S., Hwang, L., Park, S., Ghrelin regulates hippocampal neurogenesis in adult mice. Endocr. J. 56 (2009), 525–531.
168. Moore, E.M., Mander, A.G., Ames, D., Kotowicz, M.A., Carne, R.P., Brodaty, H., Woodward, M., Boundy, K., Ellis, K.A., Bush, A.I., Faux, N.G., Martins, R., Szoeke, C., Rowe, C., Watters, D.A., Investigators, A., Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes Care 36 (2013), 2981–2987.
169. Morales-Corraliza, J., Wong, H., Mazzella, M.J., Che, S., Lee, S.H., Petkova, E., Wagner, J.D., Hemby, S.E., Ginsberg, S.D., Mathews, P.M., Brain-wide insulin resistance, tau phosphorylation changes, and hippocampal neprilysin and amyloid-beta alterations in a monkey model of type 1 diabetes. J. Neurosci. 36 (2016), 4248–4258.
170. Nakagawa, S., Kim, J.E., Lee, R., Malberg, J.E., Chen, J., Steffen, C., Zhang, Y.J., Nestler, E.J., Duman, R.S., Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J. Neurosci. 22 (2002), 3673–3682.
171. Nazaribadie, M., Amini, M., Ahmadpanah, M., Asgari, K., Jamlipaghale, S., Nazaribadie, S., Executive functions and information processing in patients with type 2 diabetes in comparison to pre-diabetic patients. J. Diabetes Metab. Disorders, 13, 2014, 27.
172. Neumiller, J.J., Sonnett, T.E., Wood, L.D., Setter, S.M., Campbell, R.K., Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. Diabetes, Metab. Syndr. Obes.: Targets Therapy 3 (2010), 215–226.
173. Ng, T.P., Feng, L., Yap, K.B., Lee, T.S., Tan, C.H., Winblad, B., Long-term metformin usage and cognitive function among older adults with diabetes. J. Alzheimer's Disease: JAD 41 (2014), 61–68.
174. Ohtake, N., Saito, M., Eto, M., Seki, K., Exendin-4 promotes the membrane trafficking of the AMPA receptor GluR1 subunit and ADAM10 in the mouse neocortex. Regul. Pept. 190–191 (2014), 1–11.
175. Osborne, C., West, E., Nolan, W., McHale-Owen, H., Williams, A., Bate, C., Glimepiride protects neurons against amyloid-beta-induced synapse damage. Neuropharmacology 101 (2016), 225–236.
176. Ott, A., Stolk, R.P., van Harskamp, F., Pols, H.A., Hofman, A., Breteler, M.M., Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology 53 (1999), 1937–1942.
177. Paramo, B., Hernandez-Fonseca, K., Estrada-Sanchez, A.M., Jimenez, N., Hernandez-Cruz, A., Massieu, L., Pathways involved in the generation of reactive oxygen and nitrogen species during glucose deprivation and its role on the death of cultured hippocampal neurons. Neuroscience 167 (2010), 1057–1069.
178. Pathan, A.R., Viswanad, B., Sonkusare, S.K., Ramarao, P., Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci. 79 (2006), 2209–2216.
179. Patil, S.P., Jain, P.D., Ghumatkar, P.J., Tambe, R., Sathaye, S., Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice. Neuroscience 277 (2014), 747–754.
180. Patrone, C., Eriksson, O., Lindholm, D., Diabetes drugs and neurological disorders: new views and therapeutic possibilities. Lancet Diabetes Endocrinol. 2 (2014), 256–262.
181. Pencea, V., Bingaman, K.D., Wiegand, S.J., Luskin, M.B., Infusion of brain-derived neurotrophic factor into the lateral ventricle of the adult rat leads to new neurons in the parenchyma of the striatum, septum, thalamus, and hypothalamus. J. Neurosci. 21 (2001), 6706–6717.
182. Perez-Martin, M., Cifuentes, M., Grondona, J.M., Lopez-Avalos, M.D., Gomez-Pinedo, U., Garcia-Verdugo, J.M., Fernandez-Llebrez, P., IGF-I stimulates neurogenesis in the hypothalamus of adult rats. Eur. J. Neurosci. 31 (2010), 1533–1548.
183. Petersen, R.C., Early diagnosis of Alzheimer's disease: is MCI too late?. Curr. Alzheimer Res. 6 (2009), 324–330.
184. Petzold, A., Psotta, L., Brigadski, T., Endres, T., Lessmann, V., Chronic BDNF deficiency leads to an age-dependent impairment in spatial learning. Neurobiol. Learn. Mem. 120 (2015), 52–60.
185. Pintana, H., Apaijai, N., Chattipakorn, N., Chattipakorn, S.C., DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. J. Endocrinol. 218 (2013), 1–11.
186. Pintana, H., Apaijai, N., Pratchayasakul, W., Chattipakorn, N., Chattipakorn, S.C., Effects of metformin on learning and memory behaviors and brain mitochondrial functions in high fat diet induced insulin resistant rats. Life Sci. 91 (2012), 409–414.
187. Pipatpiboon, N., Pintana, H., Pratchayasakul, W., Chattipakorn, N., Chattipakorn, S.C., DPP4-inhibitor improves neuronal insulin receptor function, brain mitochondrial function and cognitive function in rats with insulin resistance induced by high-fat diet consumption. Eur. J. Neurosci. 37 (2013), 839–849.
188. Plastino, M., Fava, A., Pirritano, D., Cotronei, P., Sacco, N., Sperli, T., Spano, A., Gallo, D., Mungari, P., Consoli, D., Bosco, D., Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. J. Neurol. Sci. 288 (2010), 112–116.
189. Plum, L., Schubert, M., Bruning, J.C., The role of insulin receptor signaling in the brain. Trends Endocrinol. Metab.: TEM 16 (2005), 59–65.
190. Qin, W., Yang, T., Ho, L., Zhao, Z., Wang, J., Chen, L., Zhao, W., Thiyagarajan, M., MacGrogan, D., Rodgers, J.T., Puigserver, P., Sadoshima, J., Deng, H., Pedrini, S., Gandy, S., Sauve, A.A., Pasinetti, G.M., Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem. 281 (2006), 21745–21754.
191. Reger, M.A., Watson, G.S., Frey, W.H. 2nd, Baker, L.D., Cholerton, B., Keeling, M.L., Belongia, D.A., Fishel, M.A., Plymate, S.R., Schellenberg, G.D., Cherrier, M.M., Craft, S., Effects of intranasal insulin on cognition in memory-impaired older adults: modulation by APOE genotype. Neurobiol. Aging 27 (2006), 451–458.
192. Reger, M.A., Watson, G.S., Green, P.S., Wilkinson, C.W., Baker, L.D., Cholerton, B., Fishel, M.A., Plymate, S.R., Breitner, J.C., DeGroodt, W., Mehta, P., Craft, S., Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 70 (2008), 440–448.
193. Richardson, V.R., Smith, K.A., Carter, A.M., Adipose tissue inflammation: feeding the development of type 2 diabetes mellitus. Immunobiology 218 (2013), 1497–1504.
194. Rizzo, M.R., Barbieri, M., Boccardi, V., Angellotti, E., Marfella, R., Paolisso, G., Dipeptidyl peptidase-4 inhibitors have protective effect on cognitive impairment in aged diabetic patients with mild cognitive impairment. J. Gerontol. Ser. A, Biol. Sci. Med. Sci. 69 (2014), 1122–1131.
195. Roberts, R.O., Knopman, D.S., Geda, Y.E., Cha, R.H., Pankratz, V.S., Baertlein, L., Boeve, B.F., Tangalos, E.G., Ivnik, R.J., Mielke, M.M., Petersen, R.C., Association of diabetes with amnestic and nonamnestic mild cognitive impairment. Alzheimer's & Dementia: J. Alzheimer's Assoc. 10 (2014), 18–26.
196. Roriz-Filho, J.S., Sa-Roriz, T.M., Rosset, I., Camozzato, A.L., Santos, A.C., Chaves, M.L., Moriguti, J.C., Roriz-Cruz, M., (Pre)diabetes, brain aging, and cognition. Biochim. Biophys. Acta 1792 (2009), 432–443.
197. Russo, E., Citraro, R., Constanti, A., De Sarro, G., The mTOR signaling pathway in the brain: focus on epilepsy and epileptogenesis. Mol. Neurobiol. 46 (2012), 662–681.
198. Ryan, C.M., Freed, M.I., Rood, J.A., Cobitz, A.R., Waterhouse, B.R., Strachan, M.W., Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diabetes Care 29 (2006), 345–351.
199. Sakr, H.F., Effect of sitagliptin on the working memory and reference memory in type 2 diabetic Sprague-Dawley rats: possible role of adiponectin receptors 1. J. Physiol. Pharmacol.: Off. J. Polish Physiol. Soc. 64 (2013), 613–623.
200. Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., Iwamoto, T., Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol. Aging 32 (2011), 1626–1633.
201. Schubert, M., Gautam, D., Surjo, D., Ueki, K., Baudler, S., Schubert, D., Kondo, T., Alber, J., Galldiks, N., Kustermann, E., Arndt, S., Jacobs, A.H., Krone, W., Kahn, C.R., Bruning, J.C., Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. USA 101 (2004), 3100–3105.
202. Schulingkamp, R.J., Pagano, T.C., Hung, D., Raffa, R.B., Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci. Biobehav. Rev. 24 (2000), 855–872.
203. Seghieri, C., Policardo, L., Francesconi, P., Seghieri, G., Gender differences in the relationship between diabetes process of care indicators and cardiovascular outcomes. Eur. J. Pub. Health 26 (2016), 219–224.
204. Simon, D.K., Simuni, T., Elm, J., Clark-Matott, J., Graebner, A.K., Baker, L., Dunlop, S.R., Emborg, M., Kamp, C., Morgan, J.C., Ross, G.W., Sharma, S., Ravina, B., Investigators, N.N.-P., Peripheral biomarkers of Parkinson's disease progression and pioglitazone effects. J. Parkinson's Disease 5 (2015), 731–736.
205. Solmaz, V., Cinar, B.P., Yigitturk, G., Cavusoglu, T., Taskiran, D., Erbas, O., Exenatide reduces TNF-alpha expression and improves hippocampal neuron numbers and memory in streptozotocin treated rats. Eur. J. Pharmacol. 765 (2015), 482–487.
206. Sommerfield, A.J., Deary, I.J., Frier, B.M., Acute hyperglycemia alters mood state and impairs cognitive performance in people with type 2 diabetes. Diabetes Care 27 (2004), 2335–2340.
207. Spauwen, P.J., Kohler, S., Verhey, F.R., Stehouwer, C.D., van Boxtel, M.P., Effects of type 2 diabetes on 12-year cognitive change: results from the Maastricht aging study. Diabetes Care 36 (2013), 1554–1561.
208. Stanika, R.I., Winters, C.A., Pivovarova, N.B., Andrews, S.B., Differential NMDA receptor-dependent calcium loading and mitochondrial dysfunction in CA1 vs. CA3 hippocampal neurons. Neurobiol. Disease 37 (2010), 403–411.
209. Stockhorst, U., de Fries, D., Steingrueber, H.J., Scherbaum, W.A., Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans. Physiol. Behav. 83 (2004), 47–54.
210. Strachan, M.W., Reynolds, R.M., Marioni, R.E., Price, J.F., Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat. Rev. Endocrinol. 7 (2011), 108–114.
211. Sugino, T., Maruyama, M., Tanno, M., Kuno, A., Houkin, K., Horio, Y., Protein deacetylase SIRT1 in the cytoplasm promotes nerve growth factor-induced neurite outgrowth in PC12 cells. FEBS Lett. 584 (2010), 2821–2826.
212. Suh, S.W., Aoyama, K., Chen, Y., Garnier, P., Matsumori, Y., Gum, E., Liu, J., Swanson, R.A., Hypoglycemic neuronal death and cognitive impairment are prevented by poly(ADP-ribose) polymerase inhibitors administered after hypoglycemia. J. Neurosci. 23 (2003), 10681–10690.
213. Suh, S.W., Hamby, A.M., Swanson, R.A., Hypoglycemia, brain energetics, and hypoglycemic neuronal death. Glia 55 (2007), 1280–1286.
214. Tasci, I., Naharci, M.I., Bozoglu, E., Safer, U., Aydogdu, A., Yilmaz, B.F., Yilmaz, G., Doruk, H., Cognitive and functional influences of vildagliptin, a DPP-4 inhibitor, added to ongoing metformin therapy in elderly with type 2 diabetes. Endocr. Metab. Immune Disord. Drug Targets 13 (2013), 256–263.
215. Tokutake, T., Kasuga, K., Yajima, R., Sekine, Y., Tezuka, T., Nishizawa, M., Ikeuchi, T., Hyperphosphorylation of Tau induced by naturally secreted amyloid-beta at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3beta signaling pathway. J. Biol. Chem. 287 (2012), 35222–35233.
216. Toledo, E.M., Inestrosa, N.C., Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mouse model of Alzheimer's disease. Mol. Psychiatry, 15(272–285), 2010, 228.
217. Trevino, S., Aguilar-Alonso, P., Flores Hernandez, J.A., Brambila, E., Guevara, J., Flores, G., Lopez-Lopez, G., Munoz-Arenas, G., Morales-Medina, J.C., Toxqui, V., Venegas, B., Diaz, A., A high calorie diet causes memory loss, metabolic syndrome and oxidative stress into hippocampus and temporal cortex of rats. Synapse 69 (2015), 421–433.
218. Tuligenga, R.H., Intensive glycaemic control and cognitive decline in patients with type 2 diabetes: a meta-analysis. Endocrine Connect. 4 (2015), R16–R24.
219. Tuligenga, R.H., Dugravot, A., Tabak, A.G., Elbaz, A., Brunner, E.J., Kivimaki, M., Singh-Manoux, A., Midlife type 2 diabetes and poor glycaemic control as risk factors for cognitive decline in early old age: a post-hoc analysis of the Whitehall II cohort study. Lancet Diabetes Endocrinol. 2 (2014), 228–235.
220. Tzimopoulou, S., Cunningham, V.J., Nichols, T.E., Searle, G., Bird, N.P., Mistry, P., Dixon, I.J., Hallett, W.A., Whitcher, B., Brown, A.P., Zvartau-Hind, M., Lotay, N., Lai, R.Y., Castiglia, M., Jeter, B., Matthews, J.C., Chen, K., Bandy, D., Reiman, E.M., Gold, M., Rabiner, E.A., Matthews, P.M., A multi-center randomized proof-of-concept clinical trial applying [(1)(8)F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease. J. Alzheimer's Disease: JAD 22 (2010), 1241–1256.
221. Velayudhan, L., Poppe, M., Archer, N., Proitsi, P., Brown, R.G., Lovestone, S., Risk of developing dementia in people with diabetes and mild cognitive impairment. British J. Psychiatry: J Mental Sci. 196 (2010), 36–40.
222. Wang, H., Qin, J., Gong, S., Feng, B., Zhang, Y., Tao, J., Insulin-like growth factor-1 receptor-mediated inhibition of A-type K(+) current induces sensory neuronal hyperexcitability through the phosphatidylinositol 3-kinase and extracellular signal-regulated kinase 1/2 pathways, independently of Akt. Endocrinology 155 (2014), 168–179.
223. Wang, K.C., Woung, L.C., Tsai, M.T., Liu, C.C., Su, Y.H., Li, C.Y., Risk of Alzheimer's disease in relation to diabetes: a population-based cohort study. Neuroepidemiology 4 (2012), 237–244.
224. Warren, R.E., Frier, B.M., Hypoglycaemia and cognitive function. Diabetes Obes. Metab. 7 (2005), 493–503.
225. West, R.K., Ravona-Springer, R., Schmeidler, J., Leroith, D., Koifman, K., Guerrero-Berroa, E., Preiss, R., Hoffman, H., Silverman, J.M., Heymann, A., Schnaider-Beeri, M., The association of duration of type 2 diabetes with cognitive performance is modulated by long-term glycemic control. Am. J. Geriatric Psychiatry: Off. J. Am. Assoc. Geriatric Psychiatry 22 (2014), 1055–1059.
226. Winkler, A., Dlugaj, M., Weimar, C., Jockel, K.H., Erbel, R., Dragano, N., Moebus, S., Association of diabetes mellitus and mild cognitive impairment in middle-aged men and women. J. Alzheimer's Disease: JAD 42 (2014), 1269–1277.
227. Wu, X., Reiter, C.E., Antonetti, D.A., Kimball, S.R., Jefferson, L.S., Gardner, T.W., Insulin promotes rat retinal neuronal cell survival in a p70S6K-dependent manner. J. Biol. Chem. 279 (2004), 9167–9175.
228. Xiang, Q., Zhang, J., Li, C.Y., Wang, Y., Zeng, M.J., Cai, Z.X., Tian, R.B., Jia, W., Li, X.H., Insulin resistance-induced hyperglycemia decreased the activation of Akt/CREB in hippocampus neurons: molecular evidence for mechanism of diabetes-induced cognitive dysfunction. Neuropeptides 54 (2015), 9–15.
229. Xing, C., Yin, Y., Chang, R., Gong, X., He, X., Xie, Z., Effects of insulin-like growth factor 1 on synaptic excitability in cultured rat hippocampal neurons. Exp. Neurol. 205 (2007), 222–229.
230. Xu, F., Li, Z., Zheng, X., Liu, H., Liang, H., Xu, H., Chen, Z., Zeng, K., Weng, J., SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. Diabetes 63 (2014), 3637–3646.
231. Xu, Z.P., Yang, S.L., Zhao, S., Zheng, C.H., Li, H.H., Zhang, Y., Huang, R.X., Li, M.Z., Gao, Y., Zhang, S.J., Zhan, P.Y., Zhang, L.F., Deng, L., Wei, S., Liu, Y.C., Ye, J.W., Ren, H.J., Li, N., Kong, C.X., Wang, X., Fang, L., Zhou, Q.Z., Jiang, H.W., Li, J.R., Wang, Q., Ke, D., Liu, G.P., Wang, J.Z., Biomarkers for early diagnostic of mild cognitive impairment in type-2 diabetes patients: a multicentre, retrospective, nested case-control study. EBioMedicine 5 (2016), 105–113.
232. Yang, D., Nakajo, Y., Iihara, K., Kataoka, H., Yanamoto, H., Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice. Brain Res. 1517 (2013), 104–113.
233. Yang, Y., Zhang, J., Ma, D., Zhang, M., Hu, S., Shao, S., Gong, C.X., Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. J. Alzheimer's Disease: JAD 37 (2013), 637–648.
234. Ye, P., Li, L., Richards, R.G., DiAugustine, R.P., D'Ercole, A.J., Myelination is altered in insulin-like growth factor-I null mutant mice. J. Neurosci. 22 (2002), 6041–6051.
235. Yiu, A.P., Rashid, A.J., Josselyn, S.A., Increasing CREB function in the CA1 region of dorsal hippocampus rescues the spatial memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacol.: Off. Publ. Am. College Neuropsychopharmacol. 36 (2011), 2169–2186.
236. Yoo, D.Y., Kim, W., Nam, S.M., Yoo, K.Y., Lee, C.H., Choi, J.H., Won, M.H., Hwang, I.K., Yoon, Y.S., Reduced cell proliferation and neuroblast differentiation in the dentate gyrus of high fat diet-fed mice are ameliorated by metformin and glimepiride treatment. Neurochem. Res. 36 (2011), 2401–2408.
237. Yu, X.R., Jia, G.R., Gao, G.D., Wang, S.H., Han, Y., Cao, W., Neuroprotection of insulin against oxidative stress-induced apoptosis in cultured retinal neurons: involvement of phosphoinositide 3-kinase/Akt signal pathway. Acta Biochim. Biophys. Sin. 38 (2006), 241–248.
238. Zemva, J., Schubert, M., The role of neuronal insulin/insulin-like growth factor-1 signaling for the pathogenesis of Alzheimer's disease: possible therapeutic implications. CNS Neurol. Disord.: Drug Targets 13 (2014), 322–337.
239. Zhao, R.R., Xu, X.C., Xu, F., Zhang, W.L., Zhang, W.L., Liu, L.M., Wang, W.P., Metformin protects against seizures, learning and memory impairments and oxidative damage induced by pentylenetetrazole-induced kindling in mice. Biochem. Biophys. Res. Commun. 448 (2014), 414–417.
240. Zhao, W., Chen, H., Xu, H., Moore, E., Meiri, N., Quon, M.J., Alkon, D.L., Brain insulin receptors and spatial memory. Correlated changes in gene expression, tyrosine phosphorylation, and signaling molecules in the hippocampus of water maze trained rats. J. Biol. Chem. 274 (1999), 34893–34902.
241. Zhao, W., Wu, X., Xie, H., Ke, Y., Yung, W.H., Permissive role of insulin in the expression of long-term potentiation in the hippocampus of immature rats. Neuro-Signals 18 (2010), 236–245.
242. Zhao, W.Q., Alkon, D.L., Role of insulin and insulin receptor in learning and memory. Mol. Cell. Endocrinol. 177 (2001), 125–134.
243. Zhao, W.Q., Chen, H., Quon, M.J., Alkon, D.L., Insulin and the insulin receptor in experimental models of learning and memory. Eur. J. Pharmacol. 490 (2004), 71–81.
244. Zhao, Z., Liu, H., Xiao, K., Yu, M., Cui, L., Zhu, Q., Zhao, R., Li, G.D., Zhou, Y., Ghrelin administration enhances neurogenesis but impairs spatial learning and memory in adult mice. Neuroscience 257 (2014), 175–185.